+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cardiac Targeting Peptides Market - Global Forecast 2026-2032- Product Image
Cardiac Targeting Peptides Market - Global Forecast 2026-2032- Product Image
New

Cardiac Targeting Peptides Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6125846
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cardiac targeting peptides market is evolving rapidly, driven by the need for precise delivery and diagnostic solutions in cardiovascular care. Senior leaders seeking growth in cardiovascular precision medicine will find a landscape shaped by innovation, robust translational evidence, and advanced supply chain strategies.

Market Snapshot: Cardiac Targeting Peptides

The cardiac targeting peptides market increased from USD 248.80 million in 2025 to USD 263.04 million in 2026. It is projected to reach USD 340.27 million by 2032, registering a CAGR of 4.57%. Growth is attributed to escalating demand for targeted technologies that enhance selectivity, safety, and clinical translation in cardiovascular disease management. Pharmaceutical sponsors, biotechnology innovators, and clinical imaging enterprises are prioritizing solutions that bridge the gap between laboratory research and effective treatment, making market participation increasingly strategic for stakeholders.

Scope & Segmentation

This comprehensive analysis of the cardiac targeting peptides market reviews the entire value chain and provides actionable intelligence in several key segments:

  • Peptide Architecture: Includes linear, cyclic, and stabilized peptide designs engineered for higher tissue selectivity and prolonged therapeutic exposure. Advances in peptide structure underpin both efficacy and durability, supporting diverse clinical applications.
  • Targeting Biology: Focuses on molecules optimized to target the myocardium, endothelium, inflammatory cell microenvironments, or fibrotic cardiac tissues using distinctive biological markers or environmental cues, thereby advancing the selectivity of treatment and imaging agents.
  • Conjugation Strategy: Explores strategies such as direct peptide-drug conjugation, payload delivery via nanoparticles, biologic carriers, and the integration of sophisticated imaging agents to enable multifaceted clinical programs.
  • Application: Covers diverse clinical needs for therapeutic delivery and diagnostic imaging, alongside programs that integrate these approaches for comprehensive measurement of cardiovascular outcomes.
  • End-User Priorities: Addresses the differing adoption approaches among pharmaceutical and biotech organizations, translational research centers, and clinical imaging stakeholders, guiding market strategies for partnership and investment.
  • Regions: Analyzes market dynamics across North America (with a particular focus on U.S. clinical trials and manufacturing collaborations), Europe (driven by integrated innovation and regulatory harmonization), Asia-Pacific (noted for expanding peptide production infrastructure), as well as opportunities in the Middle East, Africa, and South America through centers of excellence and focused programs.
  • Technology Platforms: Evaluates the adoption of discovery engines, integrated technological platforms such as nanoparticles, exosomes, antibody conjugates, and advanced peptide stabilization chemistries that underpin the next generation of cardiac-targeting therapeutics.

Key Takeaways: Cardiac Targeting Peptides Market

  • Precision delivery remains essential, with peptides facilitating direct transport of payloads—including drugs, proteins, nucleic acids, and imaging agents—to specific cardiac tissues for improved outcomes.
  • The market is transitioning from fundamental peptide discovery to holistic solutions that integrate early target validation, robust structural design, and alignment of manufacturing processes to facilitate faster development cycles.
  • Leveraging AI and in vivo screening technologies accelerates peptide discovery, generating context-aware compounds tailored to disease stages and specific tissue remodeling patterns in cardiovascular conditions.
  • Recent advances in peptide stabilization chemistries offer improved degradation resistance and longer tissue retention, contributing to scalable synthesis methods and regulatory adherence.
  • Clinical studies are shifting focus toward functional cardiac benefits and validated translational mechanisms, increasing the importance of high-quality data throughout the product lifecycle.

Tariff Impact Shaping Sourcing and Supply Chains

Upcoming U.S. tariff actions are prompting organizations to reassess peptide manufacturing strategies, primarily affecting raw materials and consumables. Companies are increasingly adopting supplier diversification, dual-source arrangements, and preemptive risk assessment to safeguard essential inputs, such as specialized amino acids, linkers, and synthesis reagents. The balance between localized synthesis and regulatory or expertise considerations is resulting in more deliberate planning, contractual risk mitigation, and supply chain partnerships.

These evolving pressures are influencing the widespread adoption of resource-efficient, sustainable synthesis processes, while driving operational maturity in sourcing strategies and documentation through all production stages.

Methodology & Data Sources

The analysis leverages systematic reviews of peer-reviewed literature, global patent filings, clinical trial datasets, company reports, and regulatory documents. Structured interviews with domain experts across discovery, manufacturing, clinical, and business functions inform a multidimensional perspective, ensuring all insights reflect sector-specific, CMC, and practical adoption realities.

Why This Report Matters

  • Enables executives and R&D leaders to make informed portfolio, technology, and supply chain decisions for cardiovascular programs.
  • Facilitates navigation of regional, regulatory, and partnership landscapes critical for clinical and commercial success.
  • Provides benchmarks for manufacturing capacity, quality frameworks, and global scalability, supporting market entry and expansion strategies.

Conclusion

The cardiac targeting peptides market is emphasizing evidence-based translation and robust supply chain strategies. Targeted investment in advanced peptides, validated biological targets, and proactive production alignment is crucial for growth and long-term competitiveness in cardiovascular precision medicine.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cardiac Targeting Peptides Market, by Product Type
8.1. Diagnostics Peptides
8.1.1. Biomarker Detection Agents
8.1.1.1. Biosensor Probes
8.1.1.2. Elisa Probes
8.1.2. Imaging Agents
8.1.2.1. Mri Contrast Peptides
8.1.2.2. Pet Tracers
8.2. Dual Function Peptides
8.2.1. Drug Delivery Imaging Peptides
8.2.2. Imaging Therapy Peptides
8.3. Therapeutic Peptides
8.3.1. Angiogenic Peptides
8.3.1.1. Fgf Mimetic Peptides
8.3.1.2. Vegf Mimetic Peptides
8.3.2. Anti Apoptotic Peptides
8.3.2.1. Bcl2 Modulating Peptides
8.3.2.2. Caspase Inhibitor Peptides
8.3.3. Cardioprotective Peptides
8.3.3.1. Ischemia Reperfusion Injury Peptides
8.3.3.2. Myocardial Infarction Peptides
9. Cardiac Targeting Peptides Market, by Delivery System
9.1. Liposomal Conjugates
9.1.1. Conventional Liposomes
9.1.1.1. Cationic Liposomes
9.1.1.2. Neutral Liposomes
9.1.2. Stealth Liposomes
9.1.2.1. Mannose Modified Liposomes
9.1.2.2. PEGylated Liposomes
9.2. Nanoparticle Conjugates
9.2.1. Gold Nanoparticles
9.2.1.1. Rod Shaped Gold Nanoparticles
9.2.1.2. Spherical Gold Nanoparticles
9.2.2. Lipid Nanoparticles
9.2.2.1. Nanoemulsions
9.2.2.2. Solid Lipid Nanoparticles
9.2.3. Polymer Nanoparticles
9.2.3.1. Chitosan Nanoparticles
9.2.3.2. PLGA Nanoparticles
9.3. Polymer Conjugates
9.3.1. PEG Conjugates
9.3.1.1. Branched PEG Conjugates
9.3.1.2. Linear PEG Conjugates
9.3.2. PLGA Conjugates
9.3.2.1. Microparticles
9.3.2.2. Nanoparticles
10. Cardiac Targeting Peptides Market, by Molecule Type
10.1. Cyclic Peptides
10.1.1. Disulfide Cyclized
10.1.1.1. Mono Disulfide
10.1.1.2. Multi Disulfide
10.1.2. Head To Tail Cyclized
10.1.2.1. Backbone Cyclized
10.1.2.2. Side Chain Cyclized
10.2. Dendrimer Based Peptides
10.2.1. PAMAM Dendrimers
10.2.1.1. Generation 4
10.2.1.2. Generation 5
10.2.2. PPI Dendrimers
10.2.2.1. Generation 3
10.2.2.2. Generation 4
10.3. Linear Peptides
10.3.1. Long Chain Peptides
10.3.1.1. 21 To 50 Amino Acids
10.3.1.2. >50 Amino Acids
10.3.2. Short Chain Peptides
10.3.2.1. 10 To 20 Amino Acids
10.3.2.2. < 10 Amino Acids
11. Cardiac Targeting Peptides Market, by Application
11.1. Diagnostic Imaging
11.1.1. Mri Imaging
11.1.1.1. Gadolinium Conjugated Peptides
11.1.1.2. Iron Oxide Conjugated Peptides
11.1.2. PET Imaging
11.1.2.1. Fluorine 18 Labeled Peptides
11.1.2.2. Gallium 68 Labeled Peptides
11.1.3. Ultrasound Imaging
11.2. Targeted Drug Delivery
11.2.1. Hydrogel Based Delivery
11.2.1.1. Injectable Hydrogels
11.2.1.2. Thermoresponsive Hydrogels
11.2.2. Liposomal Delivery
11.2.2.1. PEGylated Liposomes
11.2.2.2. PH Sensitive Liposomes
11.2.3. Nanoparticle Delivery
11.2.3.1. Gold Nanoparticles
11.2.3.1.1. Rod Shaped Gold Nanoparticles
11.2.3.1.2. Spherical Gold Nanoparticles
11.2.3.2. Iron Oxide Nanoparticles
11.3. Therapeutic Treatment
11.3.1. Arrhythmia Control
11.3.2. Heart Failure Treatment
11.3.2.1. Hfpef Treatment Peptides
11.3.2.2. Hfref Treatment Peptides
11.3.3. Myocardial Infarction Management
11.3.3.1. Acute Mi Peptides
11.3.3.2. Chronic Mi Repair Peptides
12. Cardiac Targeting Peptides Market, by End User
12.1. Hospitals And Clinics
12.1.1. Cardiac Specialty Clinics
12.1.1.1. Outpatient Clinics
12.1.1.2. Surgical Centers
12.1.2. Tertiary Care Hospitals
12.1.2.1. Private Hospitals
12.1.2.2. Public Hospitals
12.2. Pharmaceutical Companies
12.2.1. Big Pharma
12.2.2. Biotech Firms
12.2.2.1. Mid Size Biotechs
12.2.2.2. Small Biotechs
12.3. Research Institutes
12.3.1. Academic Institutions
12.3.1.1. Government Labs
12.3.1.2. Universities
12.3.2. CROs
12.3.2.1. Clinical CROs
12.3.2.2. Preclinical CROs
13. Cardiac Targeting Peptides Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Cardiac Targeting Peptides Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Cardiac Targeting Peptides Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Cardiac Targeting Peptides Market
17. China Cardiac Targeting Peptides Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Acesion Pharma
18.6. Amgen Inc.
18.7. AstraZeneca PLC
18.8. Bristol-Myers Squibb Company
18.9. Eli Lilly and Company
18.10. Ferring Pharmaceuticals Inc.
18.11. Merck KGaA
18.12. Novartis AG
18.13. Novo Nordisk A/S
18.14. Pfizer Inc.
18.15. Sanofi S.A.
List of Figures
FIGURE 1. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CARDIAC TARGETING PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY REGION, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, 2018-2032 (USD MILLION)
TABLE 187. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY REGION, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY REGION, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, 2018-2032 (USD MILLION)
TABLE 197. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY REGION, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY GROUP, 2018-2032 (USD MILLION)
TABLE 199. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY REGION, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY GROUP, 2018-2032 (USD MILLION)
TABLE 202. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 204. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 205. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
TABLE 207. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 208. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 209. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, 2018-2032 (USD MILLION)
TABLE 211. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 212. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 215. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 218. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, 2018-2032 (USD MILLION)
TABLE 221. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 222. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 223. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY < 10 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY < 10 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 226. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY < 10 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 227. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 228. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 229. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 230. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
TABLE 232. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 233. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, 2018-2032 (USD MILLION)
TABLE 236. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 237. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 238. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 239. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 240. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 241. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 242. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 243. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 244. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
TABLE 246. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 247. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 248. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 250. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 251. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 252. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 253. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 254. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 256. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 257. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, 2018-2032 (USD MILLION)
TABLE 259. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 260. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 261. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, 2018-2032 (USD MILLION)
TABLE 263. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 264. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 265. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 266. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 267. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 268. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 269. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 270. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 271. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 272. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, 2018-2032 (USD MILLION)
TABLE 273. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 274. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 275. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 276. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 277. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 278. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 279. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 280. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 281. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 282. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
TABLE 283. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 284. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE

Companies Mentioned

The key companies profiled in this Cardiac Targeting Peptides market report include:
  • Acesion Pharma
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 263.04 Million
Forecasted Market Value ( USD ) by 2032 $ 340.27 Million
Compound Annual Growth Rate4.5%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Reports

Targeting Peptides Market - Global Forecast 2026-2032 - Product Image

Targeting Peptides Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Tumor Targeting Peptides Market - Global Forecast 2026-2032 - Product Image

Tumor Targeting Peptides Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Peptide Based Cardiovascular Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peptide Based Cardiovascular Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
MCL1 Inhibitor Drugs Clinical Trials & Market Opportunity Insights 2025 - Product Image

MCL1 Inhibitor Drugs Clinical Trials & Market Opportunity Insights 2025

  • Report
  • 80 Pages
  • Global
From
Cardiac Biomarkers Market - Types, Applications and Testing Locations - Product Image

Cardiac Biomarkers Market - Types, Applications and Testing Locations

  • Report
  • 256 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.